Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Clin Pharmacol Ther. 2018 Jul 25;104(5):933–939. doi: 10.1002/cpt.1135

Table 1.

Demographics of study participants.

Characteristic All
N=39		 Not Taking a
CYP2D6 Dependent
Drug
n=12		 Taking CYP2D6
Dependent Drug
n=27
Age, median (IQR) 58 (53, 64) 60 (58, 65) 57 (52, 63)
Male Gender, n (%) 22 (56%) 7 (58%) 15 (56%)
Race, n (%)
  Black or African American
  White
17 (44%)
22 (56%)
2 (17%)
10 (83%)
15 (56%)
12 (44%)
Hispanic Ethnicity, n (%)
  Hispanic or Latino
4 (10%)
2 (17%)
2 (7%)
CYP2D6 Genotype, n (%)
  Poor
  Intermediate
  Normal
  Ultra rapid
1 (3%)
5 (13%)
31 (79%)
2 (5%)
0 (0%)
3 (25%)
9 (75%)
0 (0%)
1 (4%)
2 (7%)
22 (81%)
2 (7%)
Number of CYP2D6 Dependent
Drugs, including metoprolol
succinate
  0
  1
  2
  3



12 (31%)
16 (41%)
8 (21%)
3 (8%)



12 (100%)
NA
NA
NA



NA
16 (59%)
8 (30%)
3 (11%)
Taking a CYP2D6 inhibitor, n 4 NA 4
DM/DX Ratio, median (IQR) 0.01 (0.01-
0.11)		 0.003 (0.003–0.005) 0.045 (0.009–0.123)
MT/MT OH Ratio, median
(IQR)		 1.80 (1.12-
4.51)		 NA 1.80 (1.12–4.51)